Summary:
- The article discusses significant clinical progress in the development of Moderna’s personalized mRNA cancer vaccines, specifically targeting melanoma and other solid tumors.
- It highlights the scientific mechanism of using mRNA technology to instruct the immune system to identify and attack patient-specific neoantigens found on cancer cells.
- The piece covers the implications of ongoing Phase 3 clinical trials and the potential for these therapies to revolutionize adjuvant cancer treatment protocols.